EGFR and breast cancer: Our findings reveal that PTM profiling provides significantly greater discriminatory power than proteome analysis alone, identifying critical pathways such as EGFR, MAPK, and Rho GTPase signaling in TN BC, and dysregulated G2/M phases in LAB subtypes.